People · Operator
Named in public records as an officer, director or promoter · active 2011–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Character Biosciences, Inc. | — | Biotechnology | Series C | $57.0M | $50.5M | 2025 |
| Naked Biome, Inc. | — | Biotechnology | Series A | $7.8M | $59.9M | 2016 |
| Second Genome, Inc. | — | Biotechnology | Series A | $5.0M | $180.8M | 2011 |
Peter DiLaura at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter DiLaura on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Corey Goodman | 1 | 13 |
| Michael Carusi | 1 | 7 |
| Jason Hafler | 1 | 6 |
| Vivek Garipalli | 1 | 5 |
| Greg Vontz | 1 | 3 |
| Matthew Winkler | 1 | 3 |
| Jason Lettmann | 1 | 2 |
| Peter Gardner | 1 | 2 |
| Nick Olsen | 1 | 2 |
| Brian Varnum | 1 | 1 |
| Reut Shema | 1 | 1 |
| Mayssa Attar | 1 | 1 |
| James Kasuboski | 1 | 1 |
| Cheng Zhang | 1 | 1 |
| Emma Taylor | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.